US2019284237A1PendingUtilityA1

Bifunctional peptide having capability to reduce inflammation and capability to facilitate differentiation of stem cells into chondrocytes and use thereof

Assignee: SEOUL NAT UNIV R&DB FOUNDATIONPriority: Mar 14, 2018Filed: Mar 10, 2019Published: Sep 19, 2019
Est. expiryMar 14, 2038(~11.6 yrs left)· nominal 20-yr term from priority
A61K 38/00A61P 19/02C07K 7/08A61K 38/10A61L 2300/41A61L 27/227A61L 27/54A61L 2300/25A61L 2430/06A61L 27/28C12N 5/0655A61L 27/22C12N 2501/998
62
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Disclosed are a bifunctional peptide having the capability to reduce inflammation and the capability to facilitate differentiation of stem cells into chondrocytes and the use thereof. Advantageously, the bifunctional peptide is useful for the prevention or treatment of arthritis accompanied by inflammation and damage of cartilage tissue due to excellent effects of reducing inflammation and facilitating differentiation of stem cells into chondrocytes, can be easily applied to various surgical regenerative treatments including orthopedic treatments, and can shorten the treatment period.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . A peptide represented by an amino acid sequence of any one of SEQ ID NOS: 4 to 8. 
     
     
         2 . The peptide according to  claim 1 , wherein the peptide is a bifunctional peptide having a capability to reduce inflammation and a capability to facilitate the differentiation of stem cells into chondrocytes. 
     
     
         3 . A method for preventing or treating arthritis, comprising administering a peptide represented by an amino acid sequence of any one of SEQ ID NOS: 1 to 8. 
     
     
         4 . The method according to  claim 3 , wherein the peptide is a bifunctional peptide having a capability to reduce inflammation and a capability to facilitate the differentiation of stem cells into chondrocytes. 
     
     
         5 . The method according to  claim 3 , wherein the peptide is prepared for injection or topical implantation. 
     
     
         6 . The method according to  claim 3 , wherein the peptide is administered at a dose of 0.001 to 1,000 mg per 1 kg of a body weight of a subject in need of treatment. 
     
     
         7 . A biomaterial for treating arthritis comprising, as an active ingredient, a peptide represented by an amino acid sequence of any one of SEQ ID NOS: 1 to 8. 
     
     
         8 . The biomaterial according to  claim 7 , wherein the peptide is a bifunctional peptide having a capability to reduce inflammation and a capability to facilitate the differentiation of stem cells into chondrocytes. 
     
     
         9 . The biomaterial according to  claim 7 , wherein the biomaterial comprises any one selected from the group consisting of a barrier membrane, a porous scaffold, and an implant for bio-implant produced in the form of a gel. 
     
     
         10 . The biomaterial according to  claim 9 , wherein the barrier membrane comprises any one selected from the group consisting of collagen, chitosan, gelatin, polylactide, polylactide glycolide and polycaprolactone. 
     
     
         11 . The biomaterial according to  claim 9 , wherein the porous scaffold comprises any one selected from the group consisting of collagen, chitosan, gelatin, hyaluronic acid, alginic acid, chondroitin sulfate, polylactide, polylactide glycolide, and polycaprolactone. 
     
     
         12 . The biomaterial according to  claim 9 , wherein the gel comprises any one selected from the group consisting of collagen, chitosan, gelatin, hyaluronic acid, alginic acid, poloxamer, propylene glycol, propylene glycol alginate, chondroitin sulfate and glycosaminoglycan. 
     
     
         13 . The biomaterial according to  claim 7 , wherein the peptide is present at a dose of 1 to 50 mg with respect to a unit weight (1 g) of the biomaterial.

Join the waitlist — get patent alerts

Track US2019284237A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.